ArticleJournal of comparative effectiveness research2026

A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa.

Amy Dymond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.